Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer

Androgen ablation therapy is the standard of care for newly diagnosed prostate cancer (PC) patients. PC that relapsed after hormonal therapy, referred to as castration-resistant PC (CRPC), often presents with metastasis (mCRPC) and is the major cause of disease lethality. The few available therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarwar, Sadia, Morozov, Viacheslav M., Purayil, Hamsa, Daaka, Yehia, Ishov, Alexander M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561175/
https://www.ncbi.nlm.nih.gov/pubmed/36229449
http://dx.doi.org/10.1038/s41419-022-05312-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561175/
https://www.ncbi.nlm.nih.gov/pubmed/36229449
http://dx.doi.org/10.1038/s41419-022-05312-8

Ejemplares similares